BioCorRx (BICX) Operating Expenses (2010 - 2026)

BioCorRx has disclosed Operating Expenses across 17 years of filings, most recently posting $1.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $1.2 million, up 9.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 51.36% YoY), and the FY2025 annual result was $5.6 million, up 9.72% from the prior year.
• Operating Expenses came in at $1.2 million for Q1 2026 at BioCorRx, up from $383067.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.7 million in Q3 2024 to a low of -$601569.0 in Q3 2025.
• The 5-year median for Operating Expenses is $1.1 million (2022), against an average of $1.0 million.
• Across the five-year window, Operating Expenses surged 70.75% in 2024 and sank 136.25% in 2025, its largest moves.
• BioCorRx's Operating Expenses stood at $1.3 million in 2022, then tumbled by 33.66% to $841650.0 in 2023, then jumped by 33.64% to $1.1 million in 2024, then slumped by 65.94% to $383067.0 in 2025, then surged by 205.57% to $1.2 million in 2026.
• The last three Operating Expenses figures came in at $1.2 million (Q1 2026), $383067.0 (Q4 2025), and -$601569.0 (Q3 2025), per Business Quant data.